SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy

Histone deacetylase inhibitors (HDACi) can reverse chemoresistance, enhance chemotherapy-induced cytotoxicity, and reduce sarcoma proliferation in cell lines and animal models. We sought to determine the safety and toxicity of mocetinostat and its ability to reverse chemoresistance when administered...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Sarcoma
Main Authors: Choy, Edwin, Ballman, Karla, Chen, James, Dickson, Mark A., Chugh, Rashmi, George, Suzanne, Okuno, Scott, Pollock, Raphael, Patel, Rajiv M., Hoering, Antje, Patel, Shreyaskumar
Formato: Artigo
Idioma:Inglês
Publicado em: Hindawi 2018
Assuntos:
Clinical Study
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6220374/
https://ncbi.nlm.nih.gov/pubmed/30473623
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2018/2068517
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados